Quick Answer
Ultragenyx Pharmaceutical Inc. reported Research And Development Expense of $750.00 million for the year ending 2025.
- Ultragenyx Pharmaceutical Inc. showed an increase of +7.4% in Research And Development Expense from 2024 to 2025.
- This data is from Ultragenyx Pharmaceutical Inc.'s annual report (Form 10-K), filed with the SEC on February 18, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Ultragenyx Pharmaceutical Inc.'s Research And Development Expense has grown by 5,833.1%.
- Historical annual values: Fiscal year 2025: $750.00 million | Fiscal year 2024: $698.00 million | Fiscal year 2023: $648.00 million | Fiscal year 2022: $705.79 million | Fiscal year 2021: $497.15 million | Fiscal year 2020: $412.08 million | Fiscal year 2019: $357.36 million | Fiscal year 2018: $294.00 million | Fiscal year 2017: $231.64 million | Fiscal year 2016: $183.20 million | Fiscal year 2015: $114.74 million | Fiscal year 2014: $45.97 million | Fiscal year 2013: $27.83 million | Fiscal year 2012: $12.64 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: